DaVita (NYSE:DVA) Insider Kathleen Alyce Waters Sells 15,405 Shares

DaVita Inc. (NYSE:DVA) insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

DaVita Stock Performance

Shares of NYSE DVA opened at $210.76 on Thursday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $213.44. The company has a market cap of $13.53 billion, a PE ratio of 19.55, a P/E/G ratio of 0.69 and a beta of 0.91. The business has a 50-day simple moving average of $179.88 and a two-hundred day simple moving average of $148.16.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The company’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DVA. NewEdge Advisors LLC lifted its holdings in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Goldman Sachs Group Inc. lifted its holdings in DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after acquiring an additional 28,739 shares during the period. Cerity Partners LLC lifted its holdings in DaVita by 7.0% in the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after acquiring an additional 172 shares during the period. Bank of Nova Scotia lifted its holdings in DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after acquiring an additional 176 shares during the period. Finally, Natixis lifted its holdings in DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after acquiring an additional 3,264 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of research reports. TD Cowen lifted their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and lifted their target price for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. UBS Group lifted their target price on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Truist Financial boosted their price target on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $199.17.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.